Absence of Interaction of Fondaparinux Sodium with Digoxin in Healthy Volunteers
- 1 January 2002
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 41 (Supplement) , 39-45
- https://doi.org/10.2165/00003088-200241002-00006
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparisonThe Lancet, 2002
- Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialThe Lancet, 2002
- Fondaparinux SodiumDrugs, 2002
- Fondaparinux Sodium Is Not Metabolised in Mammalian Liver Fractions and Does Not Inhibit Cytochrome P450-Mediated Metabolism of Concomitant DrugsClinical Pharmacokinetics, 2002
- Fondaparinux Sodium Mechanism of ActionClinical Pharmacokinetics, 2002
- The Pharmacokinetics of Fondaparinux Sodium in Healthy VolunteersClinical Pharmacokinetics, 2002
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee SurgeryNew England Journal of Medicine, 2001
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip ReplacementNew England Journal of Medicine, 2001
- Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.Journal of Biological Chemistry, 1992
- Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activityBiochemical and Biophysical Research Communications, 1983